维特波芬减弱NLRP3炎症酶激活,以缓解痛风性关节炎的爆发
Daniel C Shippy1, Tyler K Ulland2,3
1Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Journal of inflammation (London, England)
|July 16, 2025
概括
美国食品和药物管理局 (FDA) 批准的药物维特波芬有效地抑制NLRP3炎症酶,这是痛风关节炎爆发的关键驱动因素. 这项研究表明,通过减少炎症和胀来治疗痛风性关节炎,可以重新使用脊椎素.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
背景情况:
- 痛风关节炎 (GA) 涉及单酸盐 (MSU) 晶体沉积在关节中,导致炎症.
- NLRP3炎症体是GA中MSU晶体对炎症反应的关键调解者.
研究的目的:
- 确定可以减弱NLRP3炎症酶激活的药物剂,用于潜在的GA治疗.
- 评估脊素作为GA爆发的重用治疗药物.
主要方法:
- 选了FDA批准的875种药物的库,用于在骨髓衍生巨细胞 (BMDM) 中抑制NLRP3炎症酶.
- 在BMDM中评估了甲对IL-1β和IL-18分泌的作用.
- 在MSU诱导的GA爆发的小鼠模型中评估了вертепорфин的疗效,测量了脚胀和细胞因子诱导.
主要成果:
- 鉴定了五种药物,包括白素,可以抑制NLRP3炎症酶激活,而不会对BMDM产生细胞毒性.
- 维特波芬显著降低了依赖Nlrp3和卡斯巴-1的IL-1β和IL-18分泌.
- 在GA模型中,在小鼠中,特波芬治疗导致腿部胀减少,并抑制了促炎性细胞因子/化学因子和炎症酶标志物诱导.
结论:
- 维特波芬显示出强大的NLRP3炎症酶抑制活性.
- 这些研究结果支持将脊髓灰质炎作为治疗痛风关节炎爆发的新疗法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
272
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
272
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
237
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
237
Inflammatory Bowel Disease IV: Pharmacological Management
198
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
198
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
530
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
530
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239


